

1 **Exploratory analysis of pre and postoperative risk stratification tools to identify acute**
2 **kidney and myocardial injury in patients undergoing surgery for chronic subdural**
3 **haematoma**

4
5 *Daniel James Stubbs¹ (FRCA), Benjamin M Davies² (MRCS), Rowan Burnstein³ (PhD), Alexis J*
6 *Joannides⁴(PhD) , Ari Ercole²(PhD)*

7
8 **1:** Wellcome Trust Research Fellow & Honorary Specialist Registrar, University of
9 Cambridge, Division of Anaesthesia **3:** Consultant, University of Cambridge, Division of
10 Anaesthesia,

11 **2:** Clinical Research Fellow & Specialist Registrar, **4:** NIHR Brain Injury MedTech Co-
12 operative, Department of Clinical Neurosciences, University of Cambridge

13
14 Corresponding author: Daniel James Stubbs djs225@cam.ac.uk

15
16 **Short title:** Towards risk prediction in chronic subdural haematoma

17
18
19 **Sources of support:**

20
21 DJS is supported by a Wellcome Trust Clinician PhD Fellowship, overarching grant number
22 grant:204017/Z/16/Z.

23
24 The research was supported by the National Institute for Health Research (NIHR) Brain
25 Injury MedTech Co-operative based at Cambridge University Hospitals NHS Foundation
26 Trust and University of Cambridge. The views expressed are those of the author(s) and not
27 necessarily those of the NHS, NIHR or the Department of Health and Social Care.

28
29
30
31 **Conflicts of interest:**

32
33 All authors assert no conflict of interest

34
35 **Previous presentation:**

36
37 Elements of this work were previously presented at the SBNS/NACCS Brain Injury Day, Royal
38 Geographical Society, London, 6th December 2019

39
40
41
42
43
44
45
46
47

48 To the Editor

49

50 Perioperative statistical risk stratification is widespread. Such tools inform intraoperative
51 and postoperative care as part of the National Emergency Laparotomy Audit (NELA)¹.

52

53 Patients with chronic subdural haematomas (cSDH) are often elderly with significant
54 comorbidity². Despite this, there is a paucity of literature pertaining to risk stratification
55 models in this cohort³. At our centre, as part of a multidisciplinary improvement initiative
56 (the 'Improving Care in Elderly Neurosurgery Initiative' (ICENI)⁴) (Project ID:PRN7705) we
57 demonstrated a significant association between postoperative complications and length of
58 stay². As a further analysis within this cohort of operated cSDH, we explore the potential of
59 using retrospective electronic health record (EHR) data to generate prognostic statistical
60 models for the identification of two end-organ complications (myocardial injury –troponin
61 above the upper limit of normal and acute kidney injury (AKI) –a rise in serum creatinine of
62 ≥ 1.5 times baseline). Outcomes were chosen based on data availability and veracity as
63 well as clinical relevance. The integrated nature of our EHR permitted incorporation of
64 variables reflecting intraoperative management. This enabled an exploratory analysis of
65 models that, analogous to NELA, could be used preoperatively and updated postoperatively.

66

67 Logistic regression models were built using variables available prior to (age, American
68 society of Anesthesiologists (ASA) score, creatinine, antithrombotic use, inter-hospital
69 transfer, pre-operative physiological state, and comorbidities), and end of (opioid dose,
70 length of wait, time with mean arterial pressure, (MAP) <80mmHg, time with end tidal
71 carbon dioxide (ETCO₂) outside of 3-5kPa, and volatile v intravenous anaesthetic
72 maintenance), surgery. Physiological state was encapsulated on each admission day using
73 the electronic postoperative morbidity score (ePOMS)⁵(details in *supplemental digital
74 content*). Full details of variable generation are published elsewhere². Missing data was
75 handled by multiple imputation⁶. This was used in two ways. Firstly, $m=40$ imputed datasets
76 were formed to permit univariable screening (carrying forward all with $p < 0.2$) and
77 sequential simplification of the multivariable model using pooled likelihood ratio tests (LRT).
78 These models were subsequently internally validated using k -fold ($k=10$) cross-validation
79 using a 'fold then impute' strategy to minimise bias⁷. Model building and LRT results are in
80 *Supplemental Digital Content*. All analysis was conducted in R v3.5.3⁸.

81

82 This study utilised a previously identified, retrospective cohort of 531 consecutive cases of
83 primary operation for cSDH between October 2014 and January 2019, with appropriate
84 outcome data². 53 individuals suffered myocardial injury, 24 AKI. 69 had at least one 'end-
85 organ' complication. After multivariable model building (*See Supplemental Digital Content
86 Figure S2*) an admission model containing ASA, an indicator of tertiary transfer, anti-
87 thrombotic use, and admissions ePOMS score was formed (**Model 1 in Table 1**). These were
88 supplemented with significant day of surgery variables and the process repeated. The
89 resulting model contained ASA, tertiary transfer, anti-thrombotic use, day of surgery
90 ePOMS, intraoperative fentanyl dose, and time out of ETCO₂ range (**Model 2 in Table 1**).
91 Models yielded AUCs of 0.81(SD=0.01) and 0.85 (SD=0.01) after cross-validation
92 (*Supplemental Digital Content Figures S3 and S4*).

93

94 Our work, despite being a single centre study and lacking external validity, demonstrates the
95 possibility of using routinely-collected data to generate statistical models for the
96 identification of postoperative complications after cSDH surgery. The retrospective nature
97 of our data and the limitations of diagnostic and operative coding in cSDH² means we have
98 not been able to include all potentially relevant explanatory variables (e.g. severity of cSDH).
99 This is one of many challenges in developing prognostic models in cSDH. For instance, the
100 apparent protective association for transferred patients reflects right censoring, due to the
101 absence of complication data after discharge from our centre. Improved data linkage
102 between centres is required to accurately generate models to predict complications in such
103 patients.

104
105 Our pre-surgery model could be calculated in any centre as the increment in discriminatory
106 performance in model 2, although statistically significant, is likely clinically unimportant. For
107 example, the apparent protective association with fentanyl dose could be identifying a
108 subset of patients, deemed able to tolerate higher doses by their anaesthetist. The
109 increased odds seen with variation in ETCO₂ could represent patients with low cardiac
110 output or raised intracranial pressure (requiring hyperventilation).

111
112 Further work in larger cohorts, with appropriately linked outcome data, is required to
113 validate our approach and build on the exploratory analysis reported here to determine
114 clinical utility.

115 116 **Acknowledgements**

117
118 This research was funded, in whole or in part, by the Wellcome Trust, Grant number:
119 204017/Z/16/Z . A CC BY or equivalent licence is applied to the Author Accepted
120 Manuscript (AAM) arising from this submission, in accordance with the grant's open access
121 conditions.

122 123 **Supplemental Digital Content Files**

124
125 File 1: Supplementary Word File (.docx)

126
127 File 2: Supplementary Figure 2 (.pdf)

128
129 File 3: Supplementary Figure 3 (.pdf)

130
131 File 4: Supplementary Figure 4 (.pdf)

132 133 **References**

- 134 1. National Emergency Laparotomy Audit Risk Tool [Internet]. [cited 2020 Oct 22]. Available
135 from: <https://data.nela.org.uk/riskcalculator/>
- 136 2. Stubbs DJ, Davies BM, Bashford T, et al. Identification of factors associated with morbidity
137 and postoperative length of stay in surgically managed chronic subdural haematoma using electronic
138 health records: a retrospective cohort study. *BMJ Open* 2020; 10: e037385. [doi.
139 org/10.1136/bmjopen-2020-037385](https://doi.org/10.1136/bmjopen-2020-037385)

140

141 3. Kwon CS, Al-Awar O, Richards O, Izu A, Lengvenis G. Predicting Prognosis of Patients with
142 Chronic Subdural Hematoma: A New Scoring System. *World Neurosurg*; 2018; **109**: e707–14.
143 doi.org/10.1016/j.wneu.2017.10.058
144
145 4. The ‘Improving Care in Elderly Neurosurgery Initiative’ (ICENI) [Internet]. [cited 2020 Dec 4].
146 Available from: <https://www.improving-care.in/neurosurgery>
147 5. Stubbs DJ, Bowen JL, Furness RC, et al. Development and Validation of an Electronic
148 Postoperative Morbidity Score. *Anesth Analg* 2019; **129**: 935-942.
149 doi.org/10.1213/ANE.0000000000003953
150
151 6. Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological
152 and clinical research: Potential and pitfalls. *BMJ* 2009; **339**: 157–60. doi.org/10.1136/bmj.b2393
153
154
155 7. Wahl S, Boulesteix AL, Zierer A, Thorand B, Avan de Wiel M. Assessment of predictive
156 performance in incomplete data by combining internal validation and multiple imputation. *BMC*
157 *Med Res Methodol*; 2016; 16: 1–18. doi.org/10.1186/s12874-016-0239-7
158
159 8. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R
160 Foundation for Statistical Computing; 2013.
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191

192 Exploratory analysis of pre and postoperative risk stratification tools to identify acute
 193 kidney and myocardial injury in patients undergoing surgery for chronic subdural
 194 haematoma.

195

196 *Stubbs DJ, Davies BM, Burnstein R, Joannides A, Ercole A*

197

198 **Contents:**

199

200 **1) Cohort details and missing data**

201 **2) Calculation of an electronic postoperative morbidity score (ePOMS)**

202 **3) Approach to the handling of missing data**

203 **4) Univariable screening**

204 **5) Model building process (incl. excluded variables and *p* values)**

205 **6) R Code (github link)**

206

207

208 **Section 1: Cohort details and missing data**

209

210 Full details of patterns of missing data and the cohort's characteristics have been previously
 211 published and are available [here](#) and summarised briefly below.

212

213 Of note in our previously published study one patient had missing formal discharge data
 214 (and thus an inaccurate length of stay). In this study we had necessary laboratory results
 215 (and thus outcome data) to include them, giving us a total cohort of $n = 531$.

216

Variable	Median [IQR]
Age years	77 [69-84]
Creatinine $\mu\text{mol/l}$	73 [61-89]
	n (%)
Male	376 (70.8)
ASA ≥ 3	271 (61.0)*
Cognitively Impaired	270 (54.5)*
Admission GCS 15	342 (64.4)
Admission Motor Score 6	490 (92.3)
mRS ≥ 2	105 (31.0)*
Anticoagulants/Antiplatelets	233 (43.9)
CVS Disease	239 (45.0)
Heart Failure	101 (19.0)
Airways Disease	75 (14.1)

217

218 *ASA = American society of anesthesiologists score, GCS = Glasgow Coma Scale, mRS = Admission Modified*
 219 *Rankin Score, CVS = Cardiovascular, Motor score refers to score on the motor (movement) component of the*
 220 *GCS. * indicates that value is calculated only on those with recorded values (see missing data)*

221

222

223

224 Four variables had missing data;

- 225 • Baseline creatinine ($n = 46 - 8.7\%$)
- 226 • Cognitive status ($n = 36 - 6.8\%$),
- 227 • ASA score ($n = 87 - 16.1\%$),
- 228 • mRS ($n = 192 - 36.2\%$)

229 Patterns of missing data:

- 230 • mRS alone ($n = 133 - 25.0\%$)
- 231 • ASA alone ($n = 46 - 8.7\%$)
- 232 • Creatinine + mRS ($n = 13 - 2.4\%$)
- 233 • Creatinine alone ($n = 10 - 1.9\%$)
- 234 • Cognitive status + mRS ($n = 10 - 1.9\%$)
- 235 • Cognitive Status alone ($n = 9 - 1.7\%$)
- 236 • Creatinine + ASA ($n = 6 - 1.1\%$)
- 237 • Cognitive status, creatinine, mRS ($n = 5 - 0.9\%$)
- 238 • Cognitive status + Creatinine ($n = 4 - 0.8\%$)
- 239 • Cognitive status + creatinine + ASA ($n = 3 - 0.6\%$)
- 240 • Creatinine ASA + mRS ($n = 3 - 0.6\%$)
- 241 • Cognitive status + ASA + mRS ($n = 3 - 0.6\%$)
- 242 • Cognitive status + ASA + mRS + Creatinine ($n = 2 - 0.4\%$)
- 243 • Cognitive status + ASA ($n = 1 - 0.2\%$)

244

245

246

247

248

249

250

251

252

253

254

255

256 **Section 2: Calculation of an electronic postoperative morbidity score (ePOMS)**

257


258

Domain	Diagnostic Criteria	Notes
Respiratory	Need for supplementary oxygen	
Cardiovascular	HR >100 SBP <100 Positive Troponin test	
Neurological	Need for nurse special Motor/Verbal Score worse than referral* Focal neurology*	Nurse special used as surrogate for confusion/delirium Motor/Verbal Score refers to specific domains of the GCS Documented mismatch between left/right sided arm/leg strength at any stage
Renal	Rise in creatinine to $\geq 1.5x$ baseline	Baseline creatinine taken as last recorded creatinine prior to surgery.
GI	Anti-emetic administered	Anti-emetic defined by following WHO ATC codes: a04**, a03fa01, r06ae03, n05ad08
Pain	Need for IV opioids or local anaesthetic infusion	Drugs identified by following WHO ATC codes: n02aa01i, n02ab03i, n01bb01
Recurrence [%]	Reoperation	EPOMS originally identifies severe wound infection by need for further surgery. In this context reoperation for the same procedure is being used to identify re-accumulation of cSDH
Infection	Temperature $\geq 38^{\circ}\text{C}$ Receiving Antibiotics	Antibiotics defined by following WHO ATC codes: j01**
Haematological	Transfused with blood product	Including red cells, platelets, FFP, cryo-precipitate

259 *HR = Heart Rate, SBP = Systolic blood pressure, GCS = Glasgow Coma Scale, GI =*
260 *Gastrointestinal system, WHO ATC = World Health Organisation Anatomical therapeutic*
261 *chemical classification, IV = intravenous, FFP = fresh frozen plasma. If multiple potential*
262 *criteria are listed then an individual scores if any of these are met % In the original EPOMS*
263 *score this would correspond to the 'wound' category. * Indicates additional criterion*
264 *included in this variant from previously published[1]. ** indicates that all drugs below this*
265 *level of ATC code were included*

- 266 1. Stubbs DJ, Bowen JL, Furness RC, Gilder FJ, Romero-Ortuno R, Biram R, Menon DK,
 267 Ercole A (2019) Development and Validation of an Electronic Postoperative Morbidity
 268 Score. *Anesth Analg* 129(4):935–942
 269
 270

271 **Section 3: Approach to the handling of missing data**



282
 283 **Supplementary Figure S1: Approach to the handling of missing in data in model building**
 284 **(A1-A2) and in combination with k-fold cross validation for internal validation of**
 285 **generated model.**
 286

287 For assessment between exposures (variables) and outcome of interest, missing baseline
 288 variables were imputed using ‘multiple imputation using chained equations’ (MI with CE)
 289 (A1). These results were compared to complete cases results for each analysis (A2). A
 290 distinct approach was used to allow internal validation of final multivariable models. This
 291 was done with k=10 fold cross-validation. The dataset was split into test/train folds (B1),
 292 test folds were then individually imputed (B2), before being recombined (B3). Fold indices

293 created in B1 were used to perform cross validation forming sequential training (green
294 rows) and test (grey row) datasets.

295
296

297 **Section 4: Univariable screening**

298

	OR	95% Lower	95% Upper	<i>p</i>
Age per year	1.002	0.982	1.024	0.819
Male versus Female	0.641	0.378	1.086	0.099
ASA2 All versus ASA 1	0.848	0.097	7.373	0.881
ASA3	3.126	0.405	24.137	0.275
ASA4	13.260	1.612	109.067	0.017
ASA5	0.832	0.000	3.000	0.999
mRS 1 All versus mRS 0	1.042	0.500	2.171	0.913
mRS 2	1.337	0.524	3.407	0.544
mRS 3	1.846	0.674	5.056	0.234
mRS 4	0.892	0.259	3.071	0.856
Tertiary transfer versus direct admission	0.340	0.161	0.720	0.005
Cognitive Impairment	3.005	1.640	5.506	<0.001
M6 on admission versus any other motor score	0.244	0.121	0.493	<0.001
GCS 15 on admission versus any other GCS	0.396	0.237	0.661	<0.001
Creatinine per 20µmol/l	1.127	1.020	1.269	0.031
History of CVS Disease	2.410	1.426	4.072	0.001
Anticoagulant on admission	4.359	2.468	7.699	<0.001
Airways Disease	2.755	1.516	5.008	0.001
Heart Failure	1.920	1.083	3.404	0.026
Admission EPOMS per 1 domain increase	1.513	1.290	1.775	<0.001
DOS EPOMS per 1 domain increase	1.668	1.379	2.017	<0.001
Pre-op Deterioration	0.613	0.367	1.023	0.062
Length of Wait per hour	1.005	1.000	1.011	0.069
Op Time per 10 min	1.062	1.001	1.127	0.057
Volatile anaesthetic versus TIVA	0.964	0.579	1.606	0.889
Fentanyl dose per 25 mcg	0.839	0.758	0.928	<0.001
Time MAP not 80mmHg per 10 min	0.961	0.886	1.041	0.346
Time CO2 not 3-5kPa per 10 min	1.293	1.116	1.509	0.001

299 **Supplementary Table S1:** Pooled univariable analysis for the identification of end-organ
300 complications (myocardial infarction or acute kidney injury) in a cohort of 531 cases of
301 operated chronic subdural haematoma. Analysis conducted across $m = 40$ multiply imputed
302 datasets. ASA = American Society of Anesthesiologists score, CO2 = End Tidal Carbon Dioxide
303 tension, CVS = Cardiovascular System, DOS = Day of Surgery, EPOMS = Electronic
304 postoperative morbidity score, GCS = Glasgow Coma Scale, kPa = kilopascals, MAP = mean
305 arterial pressure, mcg = micrograms, min = minutes, M6 = Motor score of 6 on the Glasgow
306 coma scale, mRS = Modified Rankin Scale, TIVA = Total Intravenous Anaesthesia, Length of
307 wait = wait between admission and surgery.

308

309 **Section 5: Model building process and results for identification of end-organ** 310 **complications:**

311

312 After a process of univariable screening, all variables with $p < 0.2$ were carried forward to
313 multivariable model building. This was performed by pooling results across 40 multiply
314 imputed datasets and compared to complete cases.

315

316 **Supplementary Figure S2** demonstrates model building process. After univariable testing a
317 starting model formed from variables available to clinicians **prior to surgery** and the
318 subsequent order of exclusion of variables using backwards step regression with a threshold
319 for exclusion of $p=0.05$ on the pooled likelihood ratio test.

320

321 This final 'pre-op model' (**Model 1 in Table 1**) was then further refined by the addition of
322 information available at the conclusion of surgery (DOS = Day of Surgery variables) with an
323 equivalent process of model refinement using backwards step regression. This resulted in a
324 final 'post-op model' (**Model 2 in Table 2**).

325

326 Both models were subsequently tested using internal validation with a distinct imputation
327 method (see **Supplementary Figure S1**) and discrimination assessed using the area under
328 the receiver operator characteristic curve (ROC) (**Supplementary Material Figures S3 and**
329 **S4**)

330

331

332 **Section 6: R Code**

333

334 Although data for this cannot be made available due to its potentially sensitive nature and
335 origins within an approved service evaluation project we have made our analytical code
336 available on GitHub [here](#).

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

Supplementary Figure S2:
Summary of Multivariable model building

Starting model:

	OR	95% Lower	95% Upper	p
Male	0.610	0.331	1.119	0.110
ASA	1.670	0.953	2.926	0.073
M6 on Admission	0.720	0.276	1.882	0.502
GCS15 on Admission	0.747	0.388	1.439	0.383
Cognitive Impairment	1.727	0.810	3.682	0.157
CVS Disease	1.843	0.929	3.657	0.080
Creatinine	1.127	0.961	1.321	0.090
Airways Disease	1.580	0.758	3.290	0.221
Heart Failure	0.769	0.359	1.645	0.497
Anticoagulant	2.867	1.526	5.384	0.001
Tertiary Transfer	0.455	0.168	1.230	0.120
Admission ePOMS	1.256	1.048	1.506	0.014

Sequential removal of variables based on p

Variable removed	P prior to removal	P (LRT to previous)*
M6 on admission	0.502	0.501
Heart Failure	0.519	0.519
GCS15	0.222	0.195
Airways Disease	0.196	0.206
Male	0.114	0.144
Creatinine	0.130	0.150
Cognitive Concern	0.086	0.074
CVS Disease	0.069	0.066

ASA, Tertiary Transfer, Anticoagulation, Admission ePOMS carried forward

Add in DOS variables:

	OR	95% Lower	95% Upper	p
ASA	1.890	1.107	3.225	0.022
Tertiary Transfer	0.304	0.116	0.796	0.015
Anticoagulant Use	3.450	1.793	6.637	<0.001
Admission ePOMS	1.200	0.984	1.458	0.071
DOS ePOMS	1.300	1.035	1.630	0.024
Operation time (per 10 min)	1.020	0.944	1.104	0.603
Fentanyl dose (per 25mcg)	0.840	0.764	0.940	0.002
Time MAP <80mmHg (per 10 min)	0.949	0.856	1.053	0.325
Time outside of ETCO ₂ 3-5kPa (per 10 min)	1.308	1.072	1.594	0.008
Length of Wait (per hr)	1.005	0.999	1.011	0.120

Sequential removal of variables based on p


Variable removed	P prior to removal	P (LRT to previous)*
Operation time	0.603	0.599
Time MAP <80mmHg	0.399	0.388
Length of Wait	0.126	0.129
Admission ePOMS	0.120	0.116

Final model: ASA, Anticoagulant use, DOS ePOMS, Fentanyl dose, Time out of CO₂ range, Tertiary Transfer.

366
367
368
369

Supplementary Figure S3: Receiver Operator Characteristic (ROC) curve for model using admission variables


ROC curves generated by repeated cross-validation
Admission variables for identifying end-organ complications



370
371
372
373
374
375
376
377
378
379
380
381
382

Supplementary Figure S4: Receiver Operator Characteristic (ROC) curve for model using day-of-surgery variables

ROC curves generated by repeated cross-validation
Day of surgery variables for identifying end-organ complications



383